Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Launched by DANA-FARBER CANCER INSTITUTE · Nov 3, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to detect pancreatic cancer early in people who are at high risk. Researchers want to see if adding blood tests and a review of symptoms to the usual screening methods can help find pancreatic ductal adenocarcinoma (a type of pancreatic cancer) sooner. The study is currently looking for participants aged 30 to 74 who have certain genetic conditions or a family history of pancreatic cancer, which may put them at higher risk.

If you or a loved one qualifies for the trial, you can expect to undergo additional tests alongside the standard procedures. This could help catch any signs of cancer early when it might be easier to treat. It's important to note that individuals who have been diagnosed with pancreatic cancer in the past or have other active cancers are not eligible for this study. The trial is a great opportunity for those with specific genetic markers or family histories related to pancreatic cancer to contribute to important research that could improve early detection for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Participants must meet any of the following:
• • Individuals with pathogenic/likely pathogenic germline variants in STK11, and age ≥30 years.
• • Individuals with pathogenic/likely pathogenic germline variants in CDKN2A, and age ≥40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
• • Individuals with pathogenic/likely pathogenic germline variants in one of the other pancreatic cancer susceptibility genes (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53), and age ≥50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) AND
• • • Exocrine pancreatic cancer in ≥1 first- or second-degree relative from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant.
• • Individuals with pathogenic/likely pathogenic variants in PRSS1 AND a clinical phenotype consistent with hereditary pancreatitis, and age ≥40 years (or 20 years after onset of pancreatitis, whichever is earlier).
• * Individuals with familial pancreatic cancer including:
• • Family history of exocrine pancreatic cancer in ≥2 first-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant, OR
• • Family history of exocrine pancreatic cancer in 1 affected first-degree relative and 1 second-degree relative, even in the absence of a known pathogenic/likely pathogenic germline variant, OR
• • Family history of exocrine pancreatic cancer in ≥3 first- and/or second-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant.
• • Individuals who are undergoing clinically recommended pancreatic cancer surveillance.
• Exclusion Criteria:
• • Individuals with active or prior pancreatic ductal adenocarcinoma diagnosis.
• • Individuals with any active metastatic cancer.
• • Individuals who are unable to give informed consent.
• • Individuals who are under the age of 18 (infants, children, teenagers).
• • Individuals unable to tolerate Magnetic Resonance Imaging/Magnetic Resonance Cholangiopancreatography and Endoscopic Ultrasound.
• • Pregnant women are unlikely to be undergoing screening procedures and will not be considered eligible but can consent to the study at a later date.